Helicobacter pylori Secondary Antibiotic Resistance after One or More Eradication Failure: A Genotypic Stool Analysis Study
- PMID: 38667013
- PMCID: PMC11047300
- DOI: 10.3390/antibiotics13040336
Helicobacter pylori Secondary Antibiotic Resistance after One or More Eradication Failure: A Genotypic Stool Analysis Study
Abstract
Helicobacter pylori (H. pylori) antibiotic resistance is the leading cause for unsuccessful eradication therapy. After one or more failures, the chance of encountering secondary antibiotic resistance increases. The aim of this study was to characterize genotypic secondary resistance in a cohort of southern Italian H. pylori patients with at least one previous failure. Such patients collected stool samples using a dedicated kit (THD fecal testTM), and bacterial DNA was extracted and amplified using RT-PCR. Resistance to clarithromycin, amoxicillin, metronidazole, levofloxacin, and tetracycline was assessed using a high-resolution melting curve. We enrolled 50 patients. A total of 72% of patients failed one previous antibiotic course, 16% failed two, 10% failed three, and 2% failed four. The rate of secondary antibiotic resistance was 16% for clarithromycin, 18% for metronidazole, 14% for amoxicillin, 14% for levofloxacin, and 2% for tetracycline. Among the eight clarithromycin-resistant patients, five (62.5%) previously received a clarithromycin-based regimen. The same rate was 33.3% (3/9) for metronidazole. The only tetracycline-resistant patient had received Pylera. In conclusion, our data seem to show that, even though secondary resistance is not very high, resistance to clarithromycin could be very likely related to previous exposure to this antibiotic.
Keywords: Helicobacter pylori; PCR; antibiotic resistance; antibiotics; rescue regimen.
Conflict of interest statement
Alfredo Di Leo served as consultant for THD s.p.a.
Figures
Similar articles
-
The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing.Helicobacter. 2021 Aug;26(4):e12804. doi: 10.1111/hel.12804. Epub 2021 Apr 16. Helicobacter. 2021. PMID: 33860967
-
High incidence of antibiotic resistance amongst isolates of Helicobacter pylori collected in Nottingham, UK, between 2001 and 2018.J Med Microbiol. 2023 Nov;72(11). doi: 10.1099/jmm.0.001776. J Med Microbiol. 2023. PMID: 37962209
-
Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan.World J Gastroenterol. 2015 Oct 7;21(37):10669-74. doi: 10.3748/wjg.v21.i37.10669. World J Gastroenterol. 2015. PMID: 26457027 Free PMC article.
-
Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives from Vietnam.Gut Liver. 2019 Sep 15;13(5):483-497. doi: 10.5009/gnl18137. Gut Liver. 2019. PMID: 31009957 Free PMC article. Review.
-
Antibiotic resistance of Helicobacter pylori in Australia and New Zealand: A systematic review and meta-analysis.J Gastroenterol Hepatol. 2021 Jun;36(6):1450-1456. doi: 10.1111/jgh.15352. Epub 2021 Jan 3. J Gastroenterol Hepatol. 2021. PMID: 33217029
Cited by
-
Helicobacter pylori Infection in Children Versus Adults, Differences in Management Guidelines: Risks and Benefits of Treatment in Childhood.Helicobacter. 2025 Jul-Aug;30(4):e70063. doi: 10.1111/hel.70063. Helicobacter. 2025. PMID: 40798867 Free PMC article. Review.
-
Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker- and Proton Pump Inhibitor-Based Bismuth Quadruple Therapy for Helicobacter pylori Eradication: A Network Meta-Analysis.Gastro Hep Adv. 2025 May 16;4(9):100705. doi: 10.1016/j.gastha.2025.100705. eCollection 2025. Gastro Hep Adv. 2025. PMID: 40761703 Free PMC article. Review.
References
-
- Gu J., He F., Clifford G.M., Li M., Fan Z., Li X., Wang S., Wei W. A systematic review and meta-analysis on the relative and attributable risk of Helicobacter pylori infection and cardia and non-cardia gastric cancer. Expert Rev. Mol. Diagn. 2023;23:1251–1261. doi: 10.1080/14737159.2023.2277377. - DOI - PubMed
LinkOut - more resources
Full Text Sources